The panellists discussed the benefits of the collaboration, such as accessing new data more easily, avoiding duplication, collaborating with patients and obtaining cost-effective gold-standard results recognised by HTA bodies. Results expected in Germany with such a project were discussed. The panel also presented the encountered challenges in the implementation of the project. However, one great step forward seems to have been done, as Project Hercules is the recipient of the 2019 EURORDIS Black Pearl Company Award for Patient Engagement.
From right to left: Fleur Chandler (Chair Project Hercules Steering Group), Annika Bergman (Pricing and Market Access Europe, Sarepta), Meriem Bouslouk-Marx (Orphan drug adviser, Germany), Emily Crossley (Joint CEO Duchenne UK)